I 
116TH CONGRESS 
2D SESSION 
H. R. 6901 
To require the Secretary of Health and Human Services to provide updated 
information about COVID–19 testing to the public, and for other purposes. 
IN THE HOUSE OF REPRESENTATIVES 
MAY 15, 2020 
Ms. ESHOO introduced the following bill; which was referred to the Committee 
on Energy and Commerce 
A BILL 
To require the Secretary of Health and Human Services 
to provide updated information about COVID–19 testing 
to the public, and for other purposes. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. SHORT TITLE. 
This Act may be cited as the ‘‘COVID–19 Testing 
Inventory Act’’. 
SEC. 2. PUBLIC INFORMATION ABOUT COVID–19 DIAG-
NOSTIC TESTS. 
The Secretary of Health and Human Services, in con-
sultation with the Administrator of the Federal Emer-
gency Management Agency, the Commissioner of Food 
VerDate Sep 11 2014 
16:31 Jun 05, 2020
Jkt 099200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6201
E:\BILLS\H6901.IH
H6901
pamtmann on DSKBC07HB2PROD with BILLS
and Drugs, the Director of the Indian Health Service, and 
other Federal agencies, as appropriate, shall develop a 
public-facing inventory, which shall be made available on 
a single internet website, that provides real-time data and 
information on in vitro diagnostic tests (as defined in sec-
tion 809.3 of title 21, Code of Federal Regulations (or 
successor regulations)), for the detection of SARS–CoV– 
2 or the diagnosis of the virus that causes COVID–19, 
or for the detection of antibodies from COVID–19 (re-
ferred to in this section as ‘‘COVID–19 diagnostic tests’’), 
including— 
(1) the number and type of COVID–19 diag-
nostic tests that are available for use in each State, 
territory, or Indian Tribe, by— 
(A) county; 
(B) sites of care where the tests are avail-
able for use; 
(C) type of tests, including molecular, anti-
gen, and serological tests; and 
(D) percentage of tests that deliver rapid 
results at the point-of-care; 
(2) for each laboratory, hospital, or other health 
care facility that receives COVID–19 diagnostic 
tests, the number and type of COVID–19 diagnostic 
tests received; 
VerDate Sep 11 2014 
16:31 Jun 05, 2020
Jkt 099200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6201
E:\BILLS\H6901.IH
H6901
pamtmann on DSKBC07HB2PROD with BILLS
(3) each hospital or other health care facility 
that has the capability, capacity, and testing-related 
supplies to process COVID–19 diagnostic tests, in-
cluding test type and location by State, territory, or 
Indian Tribe; 
(4) each laboratory that has the capability, ca-
pacity, and testing-related supplies to process 
COVID–19 diagnostic tests, including test type and 
location by State, territory, or Indian Tribe; 
(5) for each COVID–19 diagnostic test listed 
pursuant to paragraph (1), the time required to re-
ceive test results, including any time for processing 
and shipping, measured in the smallest unit of meas-
urement reasonable for the particular test, whether 
minutes, hours, or days; 
(6) for each COVID–19 diagnostic test listed 
pursuant to paragraph (1), the approximate time 
per employee required to run the test; 
(7) for each COVID–19 diagnostic test listed 
pursuant to paragraph (1), each test that the Sec-
retary has authorized, cleared, or approved under 
the Federal Food, Drug, and Cosmetic Act (21 
U.S.C. 301 et seq.), or is marketed in accordance 
with applicable guidance issued by the Secretary; 
VerDate Sep 11 2014 
16:31 Jun 05, 2020
Jkt 099200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6201
E:\BILLS\H6901.IH
H6901
pamtmann on DSKBC07HB2PROD with BILLS
(8) a list of each laboratory, hospital, and other 
health care facility that has reported a shortage of 
testing-related supplies, and which such supplies are 
reported to be in shortage; 
(9) for each COVID–19 test manufacturer— 
(A) the number and type of COVID–19 di-
agnostic tests for which such manufacturer 
has— 
(i) current inventory and projected 
production capacity for the next 180 days 
for at least the 180-day period following 
the date on which such information is sub-
mitted; and 
(ii) received orders, including orders 
such manufacturer does not have capacity 
to deliver; and 
(B) a description of materials that are in 
shortage that are hindering production of 
COVID–19 diagnostic tests by amount and type 
of test; and 
(10) for each laboratory, hospital, and other 
health care facility that receives COVID–19 diag-
nostic tests, the number of samples collected per day 
and the number of results transmitted to patients 
VerDate Sep 11 2014 
16:31 Jun 05, 2020
Jkt 099200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6201
E:\BILLS\H6901.IH
H6901
pamtmann on DSKBC07HB2PROD with BILLS
(including results transmitted to health care pro-
viders for patients) per day. 
Æ 
VerDate Sep 11 2014 
16:31 Jun 05, 2020
Jkt 099200
PO 00000
Frm 00005
Fmt 6652
Sfmt 6301
E:\BILLS\H6901.IH
H6901
pamtmann on DSKBC07HB2PROD with BILLS